implementing complex and multiple clinical guidelines and identifying a strategy for encouraging consistent use of evidence-based medicine in these areas would benefit all involved.

Finally, the oncology community would benefit from developing and adopting tools and a multifaceted approach to validate and check treatment recommendations and ensure they are consistent with evidence-based medicine. These efforts would optimally include the development of automated reminder and reference systems as well as other means that more easily integrate checks and reminders about complex but important treatment guidelines for busy practitioners in everyday clinical decision making. The increasing support and pressure to adopt EMR systems provide an opportunity for oncologists to become actively involved in developing and refining decision support systems that encourage such activities. Oncologists must remain actively engaged in adopting evidence-based medicine. Inevitably, if they fail as a community to meet these challenges, complex and less helpful means of monitoring clinical guideline adherence will be imposed on them by payers and regulators.

Accepted for publication on December 10, 2009.

## Acknowledgment

We thank Pauline Karikari-Martin, MPH, MSN, RN, project officer for the Evaluation of the Second Phase of the Oncology Demonstration, Centers for Medicare & Medicaid Services. Special thanks also goes to our volunteer expert panel members, who provided valuable input throughout the evaluation of the 2006 demonstration. The analyses on which

References

- 1. Hewitt M, Simone JV (eds): Ensuring Quality Cancer Care. Washington, DC, National Academies Press, 1999
- 2. Eden J, Simone JV (eds): Assessing the Quality of Cancer Care: An Approach to Measurement in Georgia. Washington, DC, National Academies Press, 2005
- 3. Clauser SB: Use of cancer performance measures in population health: A macro-level perspective. J Natl Cancer Inst Monogr 33:142-154, 2004
- **4.** Prior M, Guerin M, Grimmer-Somers K: The effectiveness of clinical guideline implementation strategies: A synthesis of systematic review findings. J Eval Clin Pract 14:888-897, 2008
- 5. Francke AL, Smit MC, de Veer AJ, et al: Factors influencing the implementation of clinical guidelines for health care professionals: A systematic meta-review. BMC Med Inform Decis Mak 8:38, 2008
- 6. Mendelson D, Carino TV: Evidence-based medicine in the United States: De rigueur or dream deferred? Health Aff (Millwood) 24:133-136, 2005

this report is based were performed under Contract No. HHSM-500-2006-00009l/Task Order #2, jointly funded by the Centers for Medicare & Medicaid Services and the National Cancer Institute, Department of Health and Human Services, which ended in May 2009. There was no policy determination at the time of award of the contract. The content of this publication does not necessarily reflect the views or policies of the department, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. The authors assume full responsibility for the accuracy and completeness of the ideas presented.

**Authors' Disclosures of Potential Conflicts of Interest**The authors indicated no potential conflicts of interest.

**Author Contributions** 

Conception and design: Julia Doherty, Myra Tanamor

Administrative support: Julia Doherty

Collection and assembly of data: Julia Doherty, Myra Tanamor Data analysis and interpretation: Julia Doherty, Myra Tanamor, John Feigert, Judy Goldberg-Dey

Manuscript writing: Julia Doherty, Myra Tanamor, John Feigert, Judy Goldberg-Dey

**Final approval of manuscript:** Julia Doherty, Myra Tanamor, John Feigert, Judy Goldbery-Dey

Corresponding author: Julia Doherty, MHSA, L&M Policy Research, PO Box 42026, Washington, DC 20015; e-mail: JDoherty@LMpolicy research.com.

DOI: 10.1200/JOP.091083

- Cabana MD, Rand CS, Powe NR, et al: Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282:1458-1465, 1999
- 8. Timmermans S, Mauck A: The promises and pitfalls of evidence-based medicine. Health Aff (Millwood) 24:18-28, 2005
- 9. Centers for Medicare & Medicaid Services: Fact Sheets: Details for 2006 Oncology Demonstration Program. http://www.cms.hhs.gov/apps/media/press/factsheet.asp?Counter=1717&intNumPerPage=10&checkDate=&checkKey=&srchType=1&numDays=3500&srchOpt=0&srchData=&keywordType=All&chkNewsType=6&intPage=&showAll=&pYear=&year=&desc=true&cboOrder=title=
- **10.** Tanamor MA, Doherty J, Feigert J, et al: Evaluation of the second phase of the oncology demonstration: Contract No. HHSM-500-2006-00009I/Task Order #2. http://www.cms.hhs.gov/Reports/Downloads/Tanamor\_2009.pdf
- 11. Field MJ, Lohr MJ (eds): Clinical Practice Guidelines: Directions for a New Program. Washington, DC, National Academies Press, 1990

## **Commentary: Medicare's 2006 Oncology Demonstration Project: Lost in Translation?**

By Peter B. Bach, MD, MAPP

In 2005 and 2006, the Centers for Medicare & Medicaid Services (CMS) conducted demonstration projects that relied on the use of the traditional claims system to gather additional information from physicians' offices about care processes and patient outcomes. In 2005, the demonstration project focused on symptom reporting by patients. In 2006, the demonstration project focused on care process and patient status reporting by treating physicians. In both

cases, the demonstration projects were vanguards of what has become an increasing emphasis on data collection in physicians' offices in relation to quality measurement and payment rationalization.

Many policymakers believe that more data are needed from clinical encounters. Most prominently, an effort to measure care quality and, in concert, pay physicians differentially on the basis of the quality of care they provide will necessarily require more detail on what care is delivered to which patients. In oncology, basic clinical information, such as disease stage, is not captured in claim forms that are submitted for payment to Medicare and private payers (only the major disease groupings are provided). Neither are patient outcomes of any kind routinely captured and reported, whether the outcomes are clinical (such as disease recurrence or progression) or patient centered (such as symptoms of distress, pain, or other measures of quality of life).

Over the long term, most policymakers believe that this additional information will be captured through electronic health records (EHRs) that will be populated during the course of routine care. Thus, these records will allow for the free movement of detailed clinical information assignable to the responsible physician without creating additional work for clinicians. Through these EHR platforms, there will be seamless determination of quality measures, care processes, and outcomes. But in the near term, EHRs are not widely in place. This makes the key innovation of the 2005 and 2006 demonstration projects their piggybacking on the medical claims transmission process to capture additional clinical data

In this issue, Doherty et al<sup>1</sup> report on their evaluation of the 2006 demonstration project, providing readers an opportunity to consider whether the intended goals of the project were achieved or whether there were serious failings. In my view, much of what they found is worrisome. There are signs that the data submitted were not necessarily what was sought, which in my mind raises some concerns about the viability of programs that depend on physicians entering into data repositories additional clinical information that is valid and accurate for the many purposes envisioned for it.

For instance, Doherty et al<sup>1</sup> found that various CMS code descriptors had been, through a back-office version of the telephone game, rewritten and abbreviated to a point at which the original meaning was not preserved. Likewise, physicians often reported that participation in the demonstration elevated their workload and that of office staff. In interviews regarding queries about guideline adherence, physicians had widely varying views on the meaning of guideline adherence as well as different ways of determining if they were actually following guidelines.

## Reference

1. Doherty J, Tanamor M, Feigert J, et al: Oncologists' experience in reporting cancer staging and guideline adherence: Lessons from the 2006 Medicare Oncology Demonstration. J Oncol Pract 6:56-59, 2010

I confess that these results on all dimensions surprised me. I did not expect the demonstration designed by CMS—with which I was involved from the point of its conceptualization through this evaluation—to add meaningful work to the practice of office-based oncology. Likewise, I did not anticipate that practicing oncologists would be passive regarding the accuracy of the staging and disease status information they submitted on claims, even though the accuracy of that information was not a criterion for payment. In addition, in policy circles, the notion of guideline adherence is pretty well entrenched, whereas the analysis by Doherty et al¹ suggests that this is not the case in practicing physicians' offices.

Perhaps in an ideal world, there would have been no gap between what CMS (and I) expected and what Doherty et al¹ actually found. With EHRs, this may all be easier. But what I have learned is that policymakers should be extraordinarily cautious about adding more data collection tasks to a crowded clinical workflow and should also assume that the key objectives of that data collection endeavor will not be treasured as much by the practicing physicians who are asked to gather and submit data as they are by the individuals who create the programs and look forward to receiving those same data.

In this observation, I do not mean to impugn the motives or objectives of either well-meaning policymakers or clinically dedicated practitioners. Rather, I intend to remind myself and others that well-meaning steps toward improving our health care system can get lost in translation from a policymaker's desk to a patient's bedside.

Accepted for publication on January 20, 2010.

**Author's Disclosures of Potential Conflicts of Interest**The author indicated no potential conflicts of interest.

Peter B. Bach, MD, MAPP, was the senior adviser to the administrator of the Centers for Medicare & Medicaid Services in 2005 and 2006. His portfolio included the agency's cancer policy. Contact him at bachp@mskcc.org.

DOI: 10.1200/JOP.091084